(NASDAQ: BLTE) Belite Bio's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 117.08%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 22.74%.
Belite Bio's revenue in 2025 is N/A.On average, 8 Wall Street analysts forecast BLTE's revenue for 2026 to be $1,623,153,999, with the lowest BLTE revenue forecast at $0, and the highest BLTE revenue forecast at $8,354,469,113. On average, 6 Wall Street analysts forecast BLTE's revenue for 2027 to be $5,228,783,735, with the lowest BLTE revenue forecast at $1,838,778,868, and the highest BLTE revenue forecast at $8,832,503,878.
In 2028, BLTE is forecast to generate $8,498,006,848 in revenue, with the lowest revenue forecast at $2,342,370,353 and the highest revenue forecast at $13,831,818,195.